Optimal graft source for allogeneic hematopoietic stem cell transplant: Bone marrow or peripheral blood?

Janak Adhikari, Priyadarshani Sharma, Vijaya R Bhatt

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Peripheral blood (PB), compared with bone marrow graft, has higher stem cell content, leads to faster engraftment and is more convenient for collection. Consequently, the use of PB graft has significantly increased in recent years. Although the use of PB graft is acceptable or even preferred to bone marrow graft in matched related donor allogeneic transplant due to a possibility of improved survival, PB graft increases the risk of chronic graft-versus-host disease and associated long-term toxicities in the setting of matched unrelated donor allogeneic transplant. In haploidentical transplant, mitigation of graft-versus-host disease with the use of post-transplant cyclophosphamide is a hypothesis-generating possibility; however, available studies have significant limitations to draw any definite conclusion.

Original languageEnglish (US)
Pages (from-to)1823-1832
Number of pages10
JournalFuture Oncology
Volume12
Issue number15
DOIs
StatePublished - Aug 2016

Fingerprint

Hematopoietic Stem Cells
Bone Marrow
Transplants
Graft vs Host Disease
Unrelated Donors
Cyclophosphamide
Stem Cells
Tissue Donors

Keywords

  • allogeneic hematopoietic stem cell transplantation
  • graft source
  • graft-versus-host disease
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Optimal graft source for allogeneic hematopoietic stem cell transplant : Bone marrow or peripheral blood? / Adhikari, Janak; Sharma, Priyadarshani; Bhatt, Vijaya R.

In: Future Oncology, Vol. 12, No. 15, 08.2016, p. 1823-1832.

Research output: Contribution to journalReview article

@article{0a033770845448ee995af9a410e333f5,
title = "Optimal graft source for allogeneic hematopoietic stem cell transplant: Bone marrow or peripheral blood?",
abstract = "Peripheral blood (PB), compared with bone marrow graft, has higher stem cell content, leads to faster engraftment and is more convenient for collection. Consequently, the use of PB graft has significantly increased in recent years. Although the use of PB graft is acceptable or even preferred to bone marrow graft in matched related donor allogeneic transplant due to a possibility of improved survival, PB graft increases the risk of chronic graft-versus-host disease and associated long-term toxicities in the setting of matched unrelated donor allogeneic transplant. In haploidentical transplant, mitigation of graft-versus-host disease with the use of post-transplant cyclophosphamide is a hypothesis-generating possibility; however, available studies have significant limitations to draw any definite conclusion.",
keywords = "allogeneic hematopoietic stem cell transplantation, graft source, graft-versus-host disease, survival",
author = "Janak Adhikari and Priyadarshani Sharma and Bhatt, {Vijaya R}",
year = "2016",
month = "8",
doi = "10.2217/fon-2016-0106",
language = "English (US)",
volume = "12",
pages = "1823--1832",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "15",

}

TY - JOUR

T1 - Optimal graft source for allogeneic hematopoietic stem cell transplant

T2 - Bone marrow or peripheral blood?

AU - Adhikari, Janak

AU - Sharma, Priyadarshani

AU - Bhatt, Vijaya R

PY - 2016/8

Y1 - 2016/8

N2 - Peripheral blood (PB), compared with bone marrow graft, has higher stem cell content, leads to faster engraftment and is more convenient for collection. Consequently, the use of PB graft has significantly increased in recent years. Although the use of PB graft is acceptable or even preferred to bone marrow graft in matched related donor allogeneic transplant due to a possibility of improved survival, PB graft increases the risk of chronic graft-versus-host disease and associated long-term toxicities in the setting of matched unrelated donor allogeneic transplant. In haploidentical transplant, mitigation of graft-versus-host disease with the use of post-transplant cyclophosphamide is a hypothesis-generating possibility; however, available studies have significant limitations to draw any definite conclusion.

AB - Peripheral blood (PB), compared with bone marrow graft, has higher stem cell content, leads to faster engraftment and is more convenient for collection. Consequently, the use of PB graft has significantly increased in recent years. Although the use of PB graft is acceptable or even preferred to bone marrow graft in matched related donor allogeneic transplant due to a possibility of improved survival, PB graft increases the risk of chronic graft-versus-host disease and associated long-term toxicities in the setting of matched unrelated donor allogeneic transplant. In haploidentical transplant, mitigation of graft-versus-host disease with the use of post-transplant cyclophosphamide is a hypothesis-generating possibility; however, available studies have significant limitations to draw any definite conclusion.

KW - allogeneic hematopoietic stem cell transplantation

KW - graft source

KW - graft-versus-host disease

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84979777874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979777874&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0106

DO - 10.2217/fon-2016-0106

M3 - Review article

C2 - 27168462

AN - SCOPUS:84979777874

VL - 12

SP - 1823

EP - 1832

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 15

ER -